Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -4 of 4 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 70				Pharmaceutical / Industry				EMD 121974-011 EORTC 26071-22072, NCT00689221


2.		Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				EMD 121974-009 NCT00093964

Last Modified: 1/14/2009 First Published: 5/13/2008


3.		Phase II Study of Cilengitide in Younger Patients With Recurrent or Progressive High-Grade Glioma That is Refractory to Standard Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				21 and under				NCI				COG-ACNS0621 ACNS0621, NCT00679354


4.		Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma a Cancerous Tumor in the Brain and Unmethylated Gene Promoter Status

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				EMD 121974-012 NCT00813943

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute